EA202190036A1 - Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение - Google Patents

Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение

Info

Publication number
EA202190036A1
EA202190036A1 EA202190036A EA202190036A EA202190036A1 EA 202190036 A1 EA202190036 A1 EA 202190036A1 EA 202190036 A EA202190036 A EA 202190036A EA 202190036 A EA202190036 A EA 202190036A EA 202190036 A1 EA202190036 A1 EA 202190036A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crystalline form
compound
diseases
activity
application
Prior art date
Application number
EA202190036A
Other languages
English (en)
Inventor
Ицянь Ван
Чуньхуэй Чжан
Цзябин ВАН
Лемин ДИН
Original Assignee
Бетта Фармасьютикалз Ко., Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бетта Фармасьютикалз Ко., Лтд filed Critical Бетта Фармасьютикалз Ко., Лтд
Publication of EA202190036A1 publication Critical patent/EA202190036A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)

Abstract

Настоящее изобретение относится к солевой форме (R)-N-(5-((4-этилпиперазин-1-ил)метил)пиридин-2-ил)-5-фтор-4-(6-фтор-1-метил-1,2,3,4-тетрагидробензо[4,5]имидазо[1,2-a]пиридин-8-ил)пиримидин-2-амина (соединение I), как показано в структурной формуле (I), или его кристаллической форме и также относится к способу получения солевой формы соединения I и/или его кристаллической формы, фармацевтической композиции, содержащей солевую форму и/или кристаллическую форму, и их применению в получении лекарственных средств для лечения заболеваний, болезней или состояний или способу лечения заболеваний, болезней или состояний.
EA202190036A 2018-06-21 2019-06-21 Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение EA202190036A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018092194 2018-06-21
PCT/CN2019/092239 WO2019242719A1 (zh) 2018-06-21 2019-06-21 抑制cdk4/6活性化合物的晶型及其应用

Publications (1)

Publication Number Publication Date
EA202190036A1 true EA202190036A1 (ru) 2021-03-24

Family

ID=68983152

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190036A EA202190036A1 (ru) 2018-06-21 2019-06-21 Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение

Country Status (15)

Country Link
US (1) US12043622B2 (ru)
EP (1) EP3812386A4 (ru)
JP (1) JP7430656B2 (ru)
KR (1) KR20210024004A (ru)
CN (2) CN112424202B (ru)
AU (1) AU2019290722B2 (ru)
BR (1) BR112020026052A2 (ru)
CA (1) CA3104365A1 (ru)
EA (1) EA202190036A1 (ru)
IL (1) IL279579B2 (ru)
MX (1) MX2020013847A (ru)
PH (1) PH12020552236A1 (ru)
SG (1) SG11202012858QA (ru)
TW (1) TWI786303B (ru)
WO (1) WO2019242719A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202300145A (zh) * 2021-03-24 2023-01-01 大陸商貝達藥業股份有限公司 藥物組合、包含其的試劑盒及其用途
WO2023131179A1 (zh) * 2022-01-05 2023-07-13 贝达药业股份有限公司 苯并咪唑衍生物或其盐在治疗白血病中的用途
CN115872923B (zh) * 2022-12-29 2023-04-28 成都泰和伟业生物科技有限公司 一种化合物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105294655B (zh) * 2014-07-26 2019-03-15 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
CN104592251B (zh) 2015-01-23 2019-10-01 上海复星医药产业发展有限公司 4-(稠杂环取代氨基)-1h-吡唑-3-甲酰胺类化合物及其用途
TWI696617B (zh) 2015-04-28 2020-06-21 大陸商上海復尚慧創醫藥研究有限公司 特定蛋白質激酶抑制劑
EP3319962B1 (en) * 2015-07-08 2020-05-13 H. Hoffnabb-La Roche Ag Aryl sultam derivatives as rorc modulators
CN106608879A (zh) 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
WO2017102796A1 (en) * 2015-12-16 2017-06-22 F. Hoffmann-La Roche Ag HETEROARYL AMIDE SULTAM DERIVATIVES AS RORc MODULATORS
TWI646094B (zh) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
US11053238B2 (en) * 2016-12-22 2021-07-06 Betta Pharmaceuticals Co., Ltd. Benzimidazole derivatives, preparation methods and uses thereof
WO2019035008A1 (en) 2017-08-15 2019-02-21 Beijing Xuanyi Pharmasciences Co., Ltd. INHIBITORS OF CDK4 / 6 AND THEIR USE

Also Published As

Publication number Publication date
IL279579B2 (en) 2023-02-01
IL279579A (en) 2021-03-01
CN112424202A (zh) 2021-02-26
KR20210024004A (ko) 2021-03-04
CN113861191A (zh) 2021-12-31
MX2020013847A (es) 2021-04-28
JP7430656B2 (ja) 2024-02-13
SG11202012858QA (en) 2021-02-25
US20210261546A1 (en) 2021-08-26
CA3104365A1 (en) 2019-12-26
AU2019290722A1 (en) 2021-01-28
JP2021529175A (ja) 2021-10-28
BR112020026052A2 (pt) 2021-03-23
WO2019242719A1 (zh) 2019-12-26
CN112424202B (zh) 2021-09-17
TWI786303B (zh) 2022-12-11
AU2019290722B2 (en) 2023-12-21
CN113861191B (zh) 2023-09-19
US12043622B2 (en) 2024-07-23
PH12020552236A1 (en) 2021-06-28
IL279579B (en) 2022-10-01
TW202016114A (zh) 2020-05-01
EP3812386A1 (en) 2021-04-28
EP3812386A4 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
PH12020552236A1 (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
RU2650895C2 (ru) Соединения замещенных пиразолонов и способы использования
JOP20210017A1 (ar) مثبطات جسيم التهابي nlrp3
HRP20180483T1 (hr) Spoj kinolona
NZ590784A (en) Pyrazolopyridine kinase inhibitors
HRP20201094T1 (hr) IMIDAZO[1,2-a]PIRIDINI, NAMIJENJENI LIJEČENJU ILI SPRJEČAVANJU HIPERURIKEMIJE ILI GIHTA
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
AR050952A1 (es) Derivados de indazolona; procesos para su obtencion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta - hsd1.
CA2548654A1 (en) Piperidine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication
MX2015009950A (es) Compuestos de imidazopiridina y sus usos.
MX2009009843A (es) Compuestos espiro sustituidos como inhibidores de la angiogenesis.
EA201300620A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИМИДАЗО[4,5-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ JAK
ME01312B (me) Heteroaril supstituirani pirol0[2,3-b]piridini i pirol0 [ 2,3-b]pirimidini kao inhibitori janus kinaze
NZ588830A (en) Inhibitors of protein kinases
RU2015148189A (ru) ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1
EA201492112A1 (ru) ЗАМЕЩЕННЫЕ 3,4-ДИГИДРО-2H-ПИРИДО[1,2-a]ПИРАЗИН-1,6-ДИОНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ ДЛЯ ЛЕЧЕНИЯ (В ТОМ ЧИСЛЕ) БОЛЕЗНИ АЛЬЦГЕЙМЕРА
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
JP2016540803A5 (ru)
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
BRPI0408605A (pt) derivados de 8-perfluoralquil-6,7,8,9-tetrahidropirimido[1,2-a]piri midin-4-ona substituìdos
EA201691934A1 (ru) Замещенные 4,5,6,7-тетрагидро-пиразоло[1,5-альфа]пиримидиновые производные и 2,3-дигидро-1h-имидазо[1,2-бета]пиразольные производные в качестве ингибиторов ros1
PH12020500583A1 (en) 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases
PE20142244A1 (es) Inhibidores de pirazolopirimidinilo de enzima activadora de ubiquitina
MX339302B (es) 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
WO2016010869A3 (en) FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS